Gilead Experiencing Bumpy Ride Despite Strong Fundamentals

Gilead Experiencing Bumpy Ride Despite Strong Fundamentals
In December 2013, Gilead launched Sovaldi, a medicine to treat hepatitis C, and its sales boosted revenues for the calendar year 2014 which were around $ 10.3 billion. In October 2014, the company launched another drug, Harvoni, that treats a common …
Read more here.

Kidney transplant outcomes better in patients with HIV compared with HCV, HCV
Currently, guidelines suggest kidney transplantation as the preferred course of treatment for hepatitis C virus (HCV) patients; however, these patients experience worse outcomes compared with patients who are not infected with HCV. To compare the …
Read more here.

A Conversation With Steve Miller, MD: Come in and Talk With Us, Pharma
The difference with hep C was that this was the first time we had an extraordinarily high-priced drug for an extraordinarily large population. When you price a drug at almost $ 100,000 for a treatment regimen, and you have 3.2 million people that could …
Read more here.

AbbVie Inc. (NYSE:ABBV) Declares 29 Abstracts From Its Ongoing Hepatitis C
AbbVie Inc. (NYSE:ABBV) released that 29 abstracts from its ongoing hepatitis C clinical development program have been accepted for presentation during The International Liver CongressTM 2015 in Vienna, Austria from April 22-26. Data being presented …
Read more here.

PBMs: New Power and Influence
Express Scripts chose Viekira Pak's multiple-pill-per-day therapy for its national formulary after Gilead refused to budge off its $ 84,000 asking price for a course of Sovaldi, its one-dose daily hepatitis C therapy. People wondered if Express Scripts …
Read more here.

Column: Needle exchanges poke at foes
For one thing, it's only authorized for the part of Indiana experiencing the HIV outbreak. For another, it's authorized for only 30 days, a questionable … Those consequences have great gravity, however, when they involve a case of HIV or Hepatitis C …
Read more here.

AbbVie to Present New Data from Hepatitis C Clinical Development Program at
AbbVie's ongoing HCV pipeline development program focuses on investigating a pan-genotypic, ribavirin (RBV)-free, once-daily treatment that may also allow for treatment durations of as little as eight weeks. Preliminary results from a Phase 2b study (n …
Read more here.


Leave a Reply